Our results indicate that MSC could provide neuroprotective effects in ALS not only by direct release of CX3CL1 but also by stimulation of astrocytic CX3CL1 secretion and microglial CX3CR1 expression. The gene discussed is CX3CR1; the disease is amyotrophic lateral sclerosis.